FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362595589> ?p ?o ?g. }

• W4362595589 endingPage "695" @default.
• W4362595589 startingPage "695" @default.
• W4362595589 abstract "Abstract Soft-tissue sarcoma (STS) is a heterogeneous group of cancers, affecting both children and adults that develops from muscle, fat, tendons, vessels or connective tissues. Childhood STS accounts for up to 8% of all diagnosed pediatric cancer with rhabdomyosarcoma as the most common form. Prognosis depends on the type, stage and localization of the tumor, with a general 5-year survival of 70% for all STS patients. However, for patients with metastatic disease 5-year survival is 15%. The most common treatment for pediatric STS is surgery with adjuvant chemotherapy, and if possible radiotherapy. Immunotherapy, such as checkpoint blockade inhibitors (CPI), has revolutionized treatment for other malignancies such as melanoma. However, CPIs have shown limited efficacy in STS overall, and even less in pediatric patients. Thus, there is a strong need for new treatment options. Herein, we study a novel immunostimulatory gene therapy based on an oncolytic adenovirus, LOAd703, for efficacy in STS. LOAd703 is currently under clinical evaluation for several other solid cancers. LOAd703 is derived from the LOAd family of serotype 5/35 adenoviruses dependent on host cell entry via CD46. Modification of E1A has been introduced for selective replication and lysis of tumor cells. Moreover, LOAd703 is armed with the immunostimulatory genes trimerized, membrane-bound (TMZ)-CD40L and 4-1BBL expressed under control of a CMV promoter. A panel of 11 different cell lines from different STS subtypes and from both pediatric and adult patients were shown to express CD46 by flow cytometry before treatment. The cell lines were subsequently infected with LOAd703. CD46 expression was retained after infection and the infected cells upregulated the expression of the transgenes TMZ-CD40L and 4-1BBL. In addition, qPCR analysis confirmed LOAd703 replication in all tested cell lines in a time dependent manner. Replication induced oncolysis of all investigated cell lines, as analyzed by an MTS cell viability assay. In a co-culture system with peripheral blood mononuclear cells and infected sarcoma cells, preliminary results showed an alteration of markers associated with differentiation and activation among both innate and adaptive immune cells, including myeloid cells, NK cells and T cells. In conclusion, LOAd703 demonstrated a high oncolytic capacity and expression of the immunostimulatory transgenes in STS cells. Preliminary data shows that infected STS cells stimulate immune cells via the TMZ-CD40L and 4-1BBL transgenes. More in depth analysis will be performed on co-culture experiments to pinpoint the exact effect on different immune cell compartments. We are also performing multiplex analysis of proteomic changes in infected tumor cells using the OLINK® TARGET 96 assay. Finally, we willconfirm the effect of LOAd703 in vivo in a murine xenograft model for STS. Citation Format: Ahmed Calandigary, Alireza Labani-Motlagh, Darko Tamindzic, Tanja Lövgren, Emma Eriksson, Angelica Loskog. Immunostimulatory gene therapy with an oncolytic virus expressing TMZ-CD40L and 4-1BBL induces oncolysis and show immunomodulatory capacity in soft tissue sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 695." @default.
• W4362595589 created "2023-04-06" @default.
• W4362595589 creator A5004426426 @default.
• W4362595589 creator A5046265543 @default.
• W4362595589 creator A5050809581 @default.
• W4362595589 creator A5063027590 @default.
• W4362595589 creator A5080638354 @default.
• W4362595589 creator A5083572416 @default.
• W4362595589 date "2023-04-04" @default.
• W4362595589 modified "2023-09-24" @default.
• W4362595589 title "Abstract 695: Immunostimulatory gene therapy with an oncolytic virus expressing TMZ-CD40L and 4-1BBL induces oncolysis and show immunomodulatory capacity in soft tissue sarcoma" @default.
• W4362595589 doi "https://doi.org/10.1158/1538-7445.am2023-695" @default.
• W4362595589 hasPublicationYear "2023" @default.
• W4362595589 type Work @default.
• W4362595589 citedByCount "0" @default.
• W4362595589 crossrefType "journal-article" @default.
• W4362595589 hasAuthorship W4362595589A5004426426 @default.
• W4362595589 hasAuthorship W4362595589A5046265543 @default.
• W4362595589 hasAuthorship W4362595589A5050809581 @default.
• W4362595589 hasAuthorship W4362595589A5063027590 @default.
• W4362595589 hasAuthorship W4362595589A5080638354 @default.
• W4362595589 hasAuthorship W4362595589A5083572416 @default.
• W4362595589 hasConcept C104317684 @default.
• W4362595589 hasConcept C111599444 @default.
• W4362595589 hasConcept C121608353 @default.
• W4362595589 hasConcept C126322002 @default.
• W4362595589 hasConcept C142724271 @default.
• W4362595589 hasConcept C143998085 @default.
• W4362595589 hasConcept C203014093 @default.
• W4362595589 hasConcept C2777701055 @default.
• W4362595589 hasConcept C2778256501 @default.
• W4362595589 hasConcept C2778629024 @default.
• W4362595589 hasConcept C2780844630 @default.
• W4362595589 hasConcept C2993561819 @default.
• W4362595589 hasConcept C502942594 @default.
• W4362595589 hasConcept C509974204 @default.
• W4362595589 hasConcept C55493867 @default.
• W4362595589 hasConcept C71924100 @default.
• W4362595589 hasConcept C82210918 @default.
• W4362595589 hasConcept C86803240 @default.
• W4362595589 hasConceptScore W4362595589C104317684 @default.
• W4362595589 hasConceptScore W4362595589C111599444 @default.
• W4362595589 hasConceptScore W4362595589C121608353 @default.
• W4362595589 hasConceptScore W4362595589C126322002 @default.
• W4362595589 hasConceptScore W4362595589C142724271 @default.
• W4362595589 hasConceptScore W4362595589C143998085 @default.
• W4362595589 hasConceptScore W4362595589C203014093 @default.
• W4362595589 hasConceptScore W4362595589C2777701055 @default.
• W4362595589 hasConceptScore W4362595589C2778256501 @default.
• W4362595589 hasConceptScore W4362595589C2778629024 @default.
• W4362595589 hasConceptScore W4362595589C2780844630 @default.
• W4362595589 hasConceptScore W4362595589C2993561819 @default.
• W4362595589 hasConceptScore W4362595589C502942594 @default.
• W4362595589 hasConceptScore W4362595589C509974204 @default.
• W4362595589 hasConceptScore W4362595589C55493867 @default.
• W4362595589 hasConceptScore W4362595589C71924100 @default.
• W4362595589 hasConceptScore W4362595589C82210918 @default.
• W4362595589 hasConceptScore W4362595589C86803240 @default.
• W4362595589 hasIssue "7_Supplement" @default.
• W4362595589 hasLocation W43625955891 @default.
• W4362595589 hasOpenAccess W4362595589 @default.
• W4362595589 hasPrimaryLocation W43625955891 @default.
• W4362595589 hasRelatedWork W2066817268 @default.
• W4362595589 hasRelatedWork W2523222294 @default.
• W4362595589 hasRelatedWork W2792864352 @default.
• W4362595589 hasRelatedWork W2912456485 @default.
• W4362595589 hasRelatedWork W2938366447 @default.
• W4362595589 hasRelatedWork W2969533880 @default.
• W4362595589 hasRelatedWork W3083761066 @default.
• W4362595589 hasRelatedWork W3122293512 @default.
• W4362595589 hasRelatedWork W3157422419 @default.
• W4362595589 hasRelatedWork W4285082525 @default.
• W4362595589 hasVolume "83" @default.
• W4362595589 isParatext "false" @default.
• W4362595589 isRetracted "false" @default.
• W4362595589 workType "article" @default.